8-K: Mangoceuticals Enters Diabetes Market with Exclusive Rights to Diabetinol

Mangoceuticals secures exclusive rights to market and sell Diabetinol, a plant-based nutraceutical for managing blood glucose, in the U.S. and Canada, expanding into the $33 billion diabetes market.

Summary

• Mangoceuticals, Inc. has entered into a Master Distribution Agreement to exclusively market and sell Diabetinol in the United States and Canada.
• Diabetinol is a plant-based nutraceutical aimed at managing blood glucose and Hemoglobin A1c (HbA1c) levels.
• Mangoceuticals issued Navy Wharf 1,000,000 shares of restricted common stock and will pay 10% of net sales revenue from Diabetinol.
• To maintain exclusivity, Mangoceuticals must generate at least $1.5 million in gross sales from Diabetinol products within 18 months from June 1, 2025.
• Failure to meet the sales minimum results in losing exclusive rights, but can be extended for 12 months with a $5 million payment.
• The company also sold 80,000 shares of restricted common stock at $2.50 per share for a total of $200,000 in a private placement.
• Following these issuances, there are 6,248,796 shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's expansion into a new market and the potential of Diabetinol. However, there are also risks and obligations associated with the agreement.

Positives

• Mangoceuticals expands into the large and growing diabetes market.
• Diabetinol offers a potentially safer and more affordable alternative to prescription diabetes medications.
• Clinical studies support Diabetinol's efficacy in improving blood glucose management.
• The company secures exclusive rights to market and sell Diabetinol in the U.S. and Canada.
• Mangoceuticals intends to distribute Diabetinol in multiple consumer-friendly formats.

Negatives

• Failure to meet the $1.5 million sales minimum within 18 months from June 1, 2025, results in losing exclusive rights.
• The company is obligated to issue 1,000,000 shares of restricted common stock, potentially diluting existing shareholders.
• Mangoceuticals is obligated to pay 10% of net sales revenue from Diabetinol to Navy Wharf.
• The company is entering a highly competitive market with established players.

Risks

• The company may not be able to successfully market and sell Diabetinol.
• Competition from existing diabetes medications and nutraceuticals could limit market share.
• Regulatory hurdles and compliance requirements could increase costs and delay product launches.
• The company's reliance on a single product for expansion into the diabetes market increases risk.
• The company may not be able to meet the sales minimums required to maintain exclusivity.

Future Outlook

Mangoceuticals plans to distribute Diabetinol in multiple consumer-friendly formats and through various channels, including direct-to-consumer online initiatives, brick and mortar retail outlets, and affiliate marketing channels. The company believes Diabetinol can become an invaluable option for individuals looking to take charge of their metabolic health.

Management Comments

• 'Diabetinol is not a direct substitute for those prescription therapies, but the internal studies have concluded that it does offer complementary metabolic benefits in a safe, natural, and more affordable way,' said Jacob Cohen, Founder and CEO of Mangoceuticals, Inc.
• Mr. Cohen further added, 'Obtaining the exclusive rights to Diabetinol is a major milestone for Mangoceuticals.'

Industry Context

The announcement comes as the diabetes crisis escalates, with a growing demand for safer, more affordable metabolic health solutions. The company is positioning Diabetinol as a natural alternative to GLP-1 medications and metformin, targeting the large population of individuals with prediabetes and type 2 diabetes.

Comparison to Industry Standards

• The $33.66 billion addressable diabetes and metabolic health market is dominated by pharmaceutical companies like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro), which offer GLP-1 receptor agonists.
• Mangoceuticals is positioning Diabetinol as a nutraceutical alternative, similar to companies like Thorne Research and Metagenics, which offer dietary supplements for metabolic health.
• The clinical studies cited for Diabetinol are similar to those conducted by nutraceutical companies to validate the efficacy of their products, but may not be as extensive as those required for FDA-approved drugs.
• The company's distribution strategy, including direct-to-consumer online initiatives, is similar to that of other telemedicine companies like Hims & Hers and Roman.

Stakeholder Impact

• Shareholders may benefit from the company's expansion into the diabetes market.
• Customers will have access to a new plant-based nutraceutical for managing blood glucose.
• Employees may see increased job opportunities as the company grows.
• Suppliers and partners may benefit from increased sales and distribution of Diabetinol.

Next Steps

• Mangoceuticals will begin marketing and selling Diabetinol in the U.S. and Canada.
• The company will need to meet the $1.5 million sales minimum within 18 months from June 1, 2025, to maintain exclusivity.
• Mangoceuticals will continue to develop and distribute Diabetinol in multiple consumer-friendly formats.
• The company will monitor and comply with regulatory requirements for the sale of Diabetinol.

Key Dates

Keywords

Diabetinol, Mangoceuticals, Diabetes, Nutraceutical, Distribution Agreement, Blood Glucose, HbA1c, Exclusive Rights, Metabolic Health, Navy Wharf